This article was originally published on 1 February 2008 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.
The filing that changes everything
GSK Biologicals' submission of Synflorix (PHiD-CV) for regulatory approval in the European Union in February 2008 marked a watershed moment in the pneumococcal vaccine market. For the first time since Wyeth's Prevnar (PCV-7) had established its dominance of the infant immunisation market in the early 2000s, a credible challenger with a differentiated clinical profile was seeking the regulatory clearance needed to compete head-to-head in national immunisation programmes.
What makes Synflorix different
Synflorix was designed not merely as a broader serotype conjugate vaccine, but with an additional potential advantage: protection against Non-Typeable Haemophilus influenzae (NTHi) through the use of protein D as a carrier protein. NTHi is a leading cause of otitis media, and the prospect of a pneumococcal vaccine that could also reduce NTHi-related middle ear disease represented a potentially compelling clinical story, particularly in European healthcare systems where otitis media carries significant economic burden.
"Synflorix is not just a me-too product - it is a genuinely differentiated vaccine that changes the competitive calculus for the pneumococcal market in Europe."
Synflorix targets 10 pneumococcal serotypes - the same core 7 as Prevnar plus serotypes 1, 5, and 7F, which carry particular burden in developing markets
The competitive dynamics ahead
VacZine Analytics noted that the filing was the opening move in what would be a protracted battle for pneumococcal market share across Europe and international markets. Wyeth was expected to respond by accelerating the development and launch of PCV-13, which would offer broader serotype coverage than either Prevnar or Synflorix. The competitive picture was further complicated by GAVI's accelerating pneumococcal vaccine access programme for lower-income countries, where pricing and procurement would be critical determinants of market share.